Direkt zum Inhalt
Merck

AKAP79 enables calcineurin to directly suppress protein kinase A activity.

eLife (2021-10-07)
Timothy W Church, Parul Tewatia, Saad Hannan, João Antunes, Olivia Eriksson, Trevor G Smart, Jeanette Hellgren Kotaleski, Matthew G Gold
ZUSAMMENFASSUNG

Interplay between the second messengers cAMP and Ca2+ is a hallmark of dynamic cellular processes. A common motif is the opposition of the Ca2+-sensitive phosphatase calcineurin and the major cAMP receptor, protein kinase A (PKA). Calcineurin dephosphorylates sites primed by PKA to bring about changes including synaptic long-term depression (LTD). AKAP79 supports signaling of this type by anchoring PKA and calcineurin in tandem. In this study, we discovered that AKAP79 increases the rate of calcineurin dephosphorylation of type II PKA regulatory subunits by an order of magnitude. Fluorescent PKA activity reporter assays, supported by kinetic modeling, show how AKAP79-enhanced calcineurin activity enables suppression of PKA without altering cAMP levels by increasing PKA catalytic subunit capture rate. Experiments with hippocampal neurons indicate that this mechanism contributes toward LTD. This non-canonical mode of PKA regulation may underlie many other cellular processes.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Roche
cOmplete, Mini, EDTA-freier Protease-Inhibitor-Cocktail, Protease Inhibitor Cocktail Tablets provided in a glass vial, Tablets provided in a glass vial
Sigma-Aldrich
Poly-L-Lysin -hydrobromid, mol wt 30,000-70,000
Sigma-Aldrich
Anti-GFP antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
4-Nitrophenylphosphat Di-(tris)-salz, phosphatase substrate